MCs and their associated proteases, chymase (CMA1), carboxypeptidase A3, and tryptase beta 2, also modulate indirectly the systemic thrombo–inflammatory response in patients with SARS-CoV-2 pneumonia, as they induce thrombosis through activation of clotting factors and platelets, and this may affect the relatively high incidence of pulmonary thrombotic events in COVID-19 [69,72]. Here, CMA1 is linked to COVID-19.